We’re delivering dramatic results in rejuvenation and restoration to help aesthetics practitioners around the world grow their businesses. Our expanding lineup of Aesthetics products gives practices the non-invasive “gateway” innovations they need to attract new customers.
SkinPen is clinically proven to improve the appearance of facial acne scars for people age 22 and above in all skin types.1
SkinPen creates controlled micro-injuries to stimulate the body’s natural wound-healing process, while minimizing cellular damage. The result: effective remodeling of scar tissue, while keeping the overall structure of the skin intact.
Skinfuse Post-Procedure Protocol was specially formulated for microneedling. It delivers essential nutrients into skin cells to optimize the results of microneedling for 90 days and beyond. Skinfuse omits ingredients with the potential to hinder the skin’s remodeling process and further enhances microneedling treatments.
Allumera is a light-activated photodynamic cream that fits seamlessly into any aesthetic practice as a non-invasive solution for aging skin. It has been clinically proven to minimize the appearance of pores and revitalize skin for a younger-looking, clearer complexion.3 Allumera is a brilliant, non-invasive solution with minimal downtime.
1 SkinPen® U.S. intended use: The SkinPen Precision System is a microneedling device and accessories intended to be used as a treatment to improve the appearance of facial acne scars in adults aged 22 years and older. Rx only. SkinPen® international intended use: SkinPen Precision is a microneedling device that utilizes collagen induction therapy to treat melasma, acne and surgical scars. See intended use, important safety information, and clinical trial details (data on file) at skinpen.com. 2 ProGen™ intended use: The ProGen PC Kit is indicated for the rapid preparation of autologous Platelet Rich Plasma (PRP) from a small sample of blood at the patient’s point of care. The PRP is mixed with autograft/or allograft bone prior to the application to a bony defect for improving handling characteristics of the graft. 3 Revitall study of safety and efficacy of Allumera® and skin illumination in 101 subjects (data on file). Results based on a survey conducted by patients after three procedures spaced four weeks apart.